Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone
GCT, Giant Cell Tumor of Bone
ClinicalTrials.gov recordTREATMENT READING
Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.
Not medical advice · Not a complete treatment or trial directory
Made by Triangle.
Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Most treatment protocols for osteosarcoma use an initial period of systemic chemotherapy before definitive resection of the primary tumor (or resection of sites of metastases). The pathologist assesses necrosis in the resected tumor. Patients with at least 90% necrosis in the primary tumor after induction chemotherapy have a better prognosis than do patients with less necrosis.[30] Patients with less necrosis (<90%) in the primary tumor after initial chemotherapy have a higher rate of recurrence within the first 2 years than do patients with a more favorable amount of necrosis (≥90%).[43]
Less necrosis should not be interpreted to mean that chemotherapy has been ineffective. Cure rates for patients with little or no necrosis after induction chemotherapy are much higher than cure rates for patients who receive no chemotherapy. The EFS rate for patients who receive no adjuvant chemotherapy is approximately 11%.[44] Many large published series of patients treated with chemotherapy have reported EFS rates of 40% to 50% for patients with little or no necrosis in the primary tumor after initial systemic chemotherapy.[45-47] A review of two consecutive prospective trials performed by the Children’s Oncology Group showed that histological necrosis in the primary tumor after initial chemotherapy was affected by the duration and intensity of the initial period of chemotherapy. More necrosis was associated with better outcome in both trials, but the magnitude of the difference between patients with more and less necrosis was diminished with a longer and more intensive period of initial chemotherapy.[48][Level of evidence B1]
Sources: 44 · 45 · 47 · 48 · Level of evidence B1
This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
It is imperative that patients with proven or suspected osteosarcoma have an initial evaluation by an orthopedic oncologist familiar with the surgical management of this disease. This evaluation, which includes imaging studies, should be done before the initial biopsy because an inappropriately performed biopsy may jeopardize a limb-sparing procedure. Additionally, protective weight bearing is recommended for patients with tumors of weight-bearing bones to prevent pathological fractures that could preclude limb-preserving surgery.
Successful treatment generally requires the combination of effective systemic chemotherapy and complete resection of all clinically detectable disease.
Randomized clinical trials have established that both neoadjuvant and adjuvant chemotherapy are effective in preventing relapse in patients with clinically nonmetastatic tumors.[1]; [2][Level of evidence A1] The Pediatric Oncology Group (POG) conducted a study in which patients were randomly assigned to either immediate amputation or amputation after neoadjuvant therapy. A large percentage of patients declined to be assigned randomly, and the study was terminated without approaching the stated accrual goals. In the small number of patients treated, there was no difference in outcome between those who received preoperative chemotherapy and those who received postoperative chemotherapy.[3]
Sources: 1 · 2 · Level of evidence A1 · 3
The treatment of osteosarcoma also depends on the histological grade, as follows:
Low-grade osteosarcoma. Patients with low-grade osteosarcoma can be treated successfully by wide surgical resection alone, regardless of site of origin.
Intermediate-grade osteosarcoma. Pathologists sometimes characterize tumors as intermediate-grade osteosarcoma. It is difficult to make treatment decisions for patients with intermediate-grade tumors. When a tumor biopsy suggests an intermediate-grade osteosarcoma, an option is to proceed with wide resection. The availability of the entire tumor allows the pathologist to examine more tissue and evaluate soft tissue and lymphovascular invasion, which can often clarify the nature of the lesion.If the lesion proves to have high-grade elements, systemic chemotherapy is indicated, just as it would be for any high-grade osteosarcoma. The POG performed a study in which patients with high-grade osteosarcoma were randomly assigned to either immediate definitive surgery followed by adjuvant chemotherapy or to an initial period of chemotherapy followed by definitive surgery.[3] The outcome was the same for both groups. Although the strategy of initial chemotherapy followed by definitive surgery has become an almost universally applied approach for osteosarcoma, this study suggests that there is no increased risk of treatment failure if definitive surgery is done before chemotherapy begins; this can help to clarify equivocal diagnoses of intermediate-grade osteosarcoma.
Sources: 3
High-grade osteosarcoma. Patients with high-grade osteosarcoma require surgery and systemic chemotherapy. This treatment is necessary whether the tumor arises in the conventional central location or on a bone surface.
Recognition of intraosseous well-differentiated osteosarcoma and parosteal osteosarcoma is important because patients with these tumor types have the most favorable prognosis and can be treated successfully with wide excision of the primary tumor alone.[4,5] Patients with periosteal osteosarcoma have a generally good prognosis [6] and treatment is guided by histological grade.[5,7]
Patients with undifferentiated pleomorphic sarcoma (UPS) of bone are treated according to osteosarcoma treatment protocols.[8] A sarcoma-specific survival rate of 70.7% has been reported using primarily cisplatin- and doxorubicin-based regimens.[9]
Imaging modalities such as dynamic magnetic resonance imaging or positron emission tomography scanning are noninvasive methods to assess response,[10-18] and are the preferred modalities in the Children's Oncology Group AOST2032 (NCT05691478) trial.
Sources: 10 · 18 · AOST2032 (NCT05691478)
Table 3 describes the treatment options for localized, metastatic, and recurrent osteosarcoma and UPS of bone.
Sources: Table 3
| Treatment Group | Treatment Options | |
|---|---|---|
| Localized osteosarcoma and UPS of bone | Surgical removal of primary tumor. | |
| Chemotherapy. | ||
| Radiation therapy, if surgery is not feasible or surgical margins are inadequate. | ||
| Osteosarcoma and UPS of bone with metastatic disease at diagnosis: | Chemotherapy. | |
| Lung-only metastases | Preoperative chemotherapy followed by surgery to remove the tumor followed by postoperative combination chemotherapy. | |
| Bone metastases with or without lung metastases | Preoperative chemotherapy followed by surgery to remove the primary tumor and all metastatic disease followed by postoperative combination chemotherapy. | |
| Surgery to remove the primary tumor followed by chemotherapy and then surgical resection of metastatic disease followed by postoperative combination chemotherapy. | ||
| Resection of metastatic bone lesions if possible. | ||
| Radiation therapy to the extremities (may offer some local control). | ||
| Recurrent osteosarcoma and UPS of bone: | Surgery to remove all sites of metastatic disease. | |
| Chemotherapy and targeted therapy. | ||
| Radiopharmaceuticals and radiation therapy. | ||
| Local recurrence | Surgery to remove the tumor. | |
| Lung-only recurrence | Surgery to remove the tumor. | |
| Chemotherapy or targeted therapy. | ||
| Radiation therapy. | ||
| Recurrence with bone-only metastases | Surgery to remove the tumor. | |
| 153Sm-EDTMP with or without stem cell support. | ||
| Chemotherapy or targeted therapy. | ||
| Radiation therapy. | ||
| Second recurrence of osteosarcoma | Surgery to remove the tumor and/or chemotherapy. | |
| Chemotherapy or targeted therapy. | ||
| 153Sm-EDTMP = samarium Sm 153-ethylenediamine tetramethylene phosphonic acid. | ||
Sources: Surgical removal of primary tumor · Chemotherapy · Radiation therapy, if surgery is not feasible or surgical margins are inadequate · Chemotherapy · Preoperative chemotherapy followed by surgery to remove the tumor followed by postoperative combination chemotherapy · Preoperative chemotherapy followed by surgery to remove the primary tumor and all metastatic disease followed by postoperative combination chemotherapy · Surgery to remove the primary tumor followed by chemotherapy and then surgical resection of metastatic disease followed by postoperative combination chemotherapy · Resection of metastatic bone lesions if possible · Radiation therapy to the extremities (may offer some local control) · Surgery to remove all sites of metastatic disease · Chemotherapy and targeted therapy · Radiopharmaceuticals and radiation therapy · Surgery to remove the tumor · Surgery to remove the tumor · Chemotherapy or targeted therapy · Radiation therapy · Surgery to remove the tumor · 153Sm-EDTMP with or without stem cell support · Chemotherapy or targeted therapy · Radiation therapy · Surgery to remove the tumor and/or chemotherapy · Chemotherapy or targeted therapy
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:
Sources: 1
Primary care physicians.
Pediatric surgeons.
Transplant surgeons.
Pathologists.
Pediatric radiation oncologists.
Pediatric medical oncologists and hematologists.
Ophthalmologists.
Rehabilitation specialists.
Pediatric oncology nurses.
Social workers.
Child-life professionals.
Psychologists.
Nutritionists.
For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.
Sources: Supportive and Palliative Care
The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.
Sources: 2 · NCI website
Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Patients with localized osteosarcoma who undergo surgery and chemotherapy have a 5-year overall survival (OS) rate of 62% to 65%.[1] Complete surgical resection is crucial for patients with localized osteosarcoma, but it is not sufficient as the only therapy. At least 80% of patients treated with surgery alone will develop metastatic disease.[2] Randomized clinical trials have established that adjuvant chemotherapy is effective in preventing relapse or recurrence in patients with localized resectable primary tumors.[2]; [3][Level of evidence A1]
Sources: 1 · 2 · 2 · 3 · Level of evidence A1
Undifferentiated pleomorphic sarcoma (UPS) of bone is seen more commonly in older adults. Patients with UPS of bone are treated according to osteosarcoma treatment protocols. The outcome for patients with resectable UPS is similar to the outcome for patients with osteosarcoma.[4] As with osteosarcoma, patients with favorable necrosis (≥90% necrosis) have a longer survival than do those with an inferior necrosis (<90% necrosis).[5] Many patients with UPS will need preoperative chemotherapy to achieve a wide local excision.[6]
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Treatment options for patients with localized osteosarcoma or UPS of bone include the following:
Surgical removal of primary tumor.
Sources: Surgical removal of primary tumor
Chemotherapy (may start before or after definitive surgical resection of the primary tumor).
Sources: Chemotherapy
Radiation therapy, if surgery is not feasible or surgical margins are inadequate.
Sources: Radiation therapy, if surgery is not feasible or surgical margins are inadequate
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Surgical resection of the primary tumor with adequate margins is an essential component of the curative strategy for patients with localized osteosarcoma. The type of surgery required for complete ablation of the primary tumor depends on a number of factors that must be evaluated on a case-by-case basis.[7]
Sources: 7
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
In general, more than 80% of patients with extremity osteosarcoma can be treated using a limb-sparing procedure and do not require amputation.[8] Limb-sparing procedures are planned only when the preoperative staging indicates that it would be possible to achieve wide surgical margins. In one study, patients who underwent limb-salvage procedures who had poor histological response and close surgical margins had a high rate of local recurrence.[9]
Reconstruction after limb-sparing surgery can be accomplished with many options, including metallic endoprosthesis, allograft, vascularized autologous bone graft, and rotationplasty. An additional option, osteogenesis distraction bone transport, is available for patients whose tumors do not involve the epiphysis of long bones.[10] This procedure results in a stable reconstruction that functionally restores the normal limb.
Sources: 10
The choice of optimal surgical reconstruction involves many factors, including the following:[11][Level of evidence A1]
Sources: 11 · Level of evidence A1
Site and size of the primary tumor.
Ability to preserve the neurovascular supply of the distal extremity.
Age of the patient and potential for additional growth.
Needs and desires of the patient and family for specific functions such as sports participation.
If a complicated reconstruction delays or prohibits the resumption of systemic chemotherapy, limb preservation may endanger the chance for cure. In retrospective analyses of 703 patients with localized osteosarcoma, the resumption of chemotherapy 21 days or more after definitive surgery was associated with an increased risk of death and adverse events (hazard ratio [HR], 1.57; 1.04–2.36).[11] Delays in total time to completion of chemotherapy have also been associated with inferior OS and event-free survival (EFS). In a retrospective multivariate analysis of 113 patients with localized osteosarcoma, a delay of time to completion of chemotherapy greater than 4 weeks was associated with an OS HR of 2.70 (1.11–6.76, P = .003) and an EFS HR of 1.13 (1.00–1.26, P = .016).[12]
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
For some patients, amputation remains the optimal choice for management of the primary tumor. A pathological fracture noted at diagnosis or during preoperative chemotherapy does not preclude limb-salvage surgery if wide surgical margins can be achieved.[13] If the pathological examination of the surgical specimen shows inadequate margins, an immediate amputation should be considered, especially if the histological necrosis after preoperative chemotherapy was poor.[14]
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Patients who undergo amputation have lower local recurrence rates than do patients who undergo limb-salvage procedures.[15] However, there is no difference in OS between patients initially treated with amputation and those treated with a limb-sparing procedure. Patients with tumors of the femur have a higher local recurrence rate than do patients with primary tumors of the tibia or fibula. Rotationplasty and other limb-salvage procedures have been evaluated for both their functional outcome and their effect on survival. While limb-sparing resection is the current practice for local control at most pediatric institutions, there are few data to indicate that salvage of the lower limb is substantially superior to amputation with regard to patient quality of life.[16]
The German Cooperative Osteosarcoma Study Group (COSS) performed a retrospective analysis of 1,802 patients with localized and metastatic osteosarcoma who underwent surgical resection of all clinically detectable disease.[17][Level of evidence C1] Local recurrence (n = 76) was associated with a high risk of death from osteosarcoma. Factors associated with an increased risk of local recurrence included nonparticipation in a clinical trial, pelvic primary site, limb-preserving surgery, soft tissue infiltration beyond the periosteum, poor pathological response to initial chemotherapy, failure to complete planned chemotherapy, and performing the biopsy at an institution different from where the definitive surgery is being performed.
Sources: 17 · Level of evidence C1
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Almost all patients receive intravenous preoperative chemotherapy as initial treatment. However, a standard chemotherapy regimen has not been determined. Current chemotherapy protocols include combinations of the following agents: high-dose methotrexate, doxorubicin, cyclophosphamide, cisplatin, ifosfamide, etoposide, and carboplatin.[18-26]
Evidence (preoperative chemotherapy):
A meta-analysis of protocols for the treatment of osteosarcoma concluded the following:[27]
Sources: 27
A meta-analysis of protocols for the treatment of osteosarcoma concluded the following:[27]
Regimens containing three active chemotherapy agents were superior to regimens containing two active agents.
Regimens with four active agents were not superior to regimens with three active agents.
Three-drug regimens that did not include high-dose methotrexate were inferior to three-drug regimens that did include high-dose methotrexate.
An Italian study that used regimens containing fewer courses of high-dose methotrexate observed the following results:[28][Level of evidence B4]
Sources: 28 · Level of evidence B4
An Italian study that used regimens containing fewer courses of high-dose methotrexate observed the following results:[28][Level of evidence B4]
There was a lower probability for EFS than found in earlier studies that used regimens containing more courses of high-dose methotrexate.
The Children's Oncology Group (COG) performed a prospective randomized trial in newly diagnosed children and young adults with localized osteosarcoma. All patients received cisplatin, doxorubicin, and high-dose methotrexate. One-half of the patients were randomly assigned to receive ifosfamide. In a second randomization, one-half of the patients were assigned to receive the biological compound muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) beginning after definitive surgical resection. Results showed that:[29][Level of evidence A1]
Sources: 29 · Level of evidence A1
The Children's Oncology Group (COG) performed a prospective randomized trial in newly diagnosed children and young adults with localized osteosarcoma. All patients received cisplatin, doxorubicin, and high-dose methotrexate. One-half of the patients were randomly assigned to receive ifosfamide. In a second randomization, one-half of the patients were assigned to receive the biological compound muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) beginning after definitive surgical resection. Results showed that:[29][Level of evidence A1]
The addition of ifosfamide did not improve outcome.
The addition of L-MTP-PE produced improvement in the EFS rate, which did not meet the conventional test for statistical significance (P = .08), and a significant improvement in the OS rate (78% vs. 70%; P = .03).
There has been speculation regarding the potential contribution of postrelapse treatment, although there were no differences in the postrelapse surgical approaches in the relapsed patients. The appropriate role of L-MTP-PE in the treatment of osteosarcoma remains under discussion.[30]
Sources: 30
The COG performed a series of pilot studies in patients with newly diagnosed localized osteosarcoma.[31][Level of evidence B4] The results of these pilot studies were as follows:
Sources: 31 · Level of evidence B4
The COG performed a series of pilot studies in patients with newly diagnosed localized osteosarcoma.[31][Level of evidence B4] The results of these pilot studies were as follows:
In pilot study 1, patients with lower degrees of necrosis after three-drug initial therapy received subsequent therapy with a higher cumulative dose of doxorubicin of 600 mg/m2.
In pilot study 2, all patients received four-drug initial chemotherapy with cisplatin, doxorubicin, high-dose methotrexate, and ifosfamide. Patients with lower degrees of necrosis received subsequent chemotherapy with a higher cumulative dose of doxorubicin of 600 mg/m2.
In pilot study 3, all patients received the same four-drug initial chemotherapy as pilot study 2. Patients with lower degrees of necrosis received higher doses of ifosfamide with the addition of etoposide in subsequent therapy.
Outcomes for all three pilot studies were similar to each other and to historical controls.
All patients received dexrazoxane before each dose of doxorubicin. The addition of dexrazoxane did not appear to decrease the rate of good necrosis after initial therapy or EFS.
Left ventricular fractional shortening, as measured by echocardiography, was minimally affected at 78 weeks from study entry.
There was no evidence for an increased risk of secondary leukemia.
The international European and American Osteosarcoma Study (EURAMOS) Group consortium was formed to conduct a large, prospective, randomized trial to help determine whether modifying the chemotherapy regimen on the basis of the degree of necrosis would improve EFS. All patients received initial therapy with cisplatin, doxorubicin, and high-dose methotrexate (MAP). Patients with more than 90% necrosis were randomly assigned to continue the same chemotherapy after surgery or to receive the same chemotherapy with the addition of interferon alpha-2B. Patients with less than 90% necrosis were randomly assigned to continue the same chemotherapy or to receive the same chemotherapy with the addition of high-dose ifosfamide and etoposide (MAPIE).[32][Level of evidence A1]
Sources: 32 · Level of evidence A1
The international European and American Osteosarcoma Study (EURAMOS) Group consortium was formed to conduct a large, prospective, randomized trial to help determine whether modifying the chemotherapy regimen on the basis of the degree of necrosis would improve EFS. All patients received initial therapy with cisplatin, doxorubicin, and high-dose methotrexate (MAP). Patients with more than 90% necrosis were randomly assigned to continue the same chemotherapy after surgery or to receive the same chemotherapy with the addition of interferon alpha-2B. Patients with less than 90% necrosis were randomly assigned to continue the same chemotherapy or to receive the same chemotherapy with the addition of high-dose ifosfamide and etoposide (MAPIE).[32][Level of evidence A1]
At a median follow-up of 54 months for all registered patients (N = 2,260), the 3-year EFS rate was 59% (95% confidence interval [CI], 57%–61%), and the 5-year EFS rate was 54% (95% CI, 52%–56%).
The 3-year OS rate was 79% (95% CI, 77%–81%), and the 5-year OS rate was 71% (95% CI, 68%–73%).
Patients with localized disease at diagnosis (M0) who underwent complete surgical resection (n = 1,549) had 3-year EFS and OS rates from surgery of 70% and 88%, respectively; the 5-year EFS and OS rates from surgery were 64% and 79%, respectively.
Forty percent of patients/families who participated in the study declined randomization after definitive surgical resection, making interpretation of the outcome of the randomized study questions more difficult and challenging the generalizability of the results.
Of patients with more than 90% necrosis, 716 were randomly assigned to continue the same chemotherapy after surgery with or without the addition of interferon alpha-2B. The 3-year EFS rates were 74% (95% CI, 69%–79%) for patients who received MAP and 77% (95% CI, 72%–81%) for patients who received MAP plus interferon alpha-2B. The HR was 0.83 (95% CI, 0.61–1.12; P = .2).[33]
Sources: 33
Of patients with less than 90% necrosis, 618 were randomly assigned to continue MAP chemotherapy or to receive MAPIE chemotherapy. The 3-year EFS estimates for patients with localized disease were 60% (95% CI, 54%–66%) for the MAP group and 57% (95% CI, 51%–63%) for the MAPIE group. The HR was 1.03 (0.81–1.33, P = .80).[34]
Sources: 34
In a French Sarcoma Group trial, high-dose methotrexate was omitted for adult patients with osteosarcoma. The cohort included 60 patients aged 16 to 63 years (median age, 27 years). Patients received initial therapy with ifosfamide and cisplatin. Doxorubicin was added after definitive surgery for patients who had less necrosis after initial chemotherapy.[35]
Sources: 35
In a French Sarcoma Group trial, high-dose methotrexate was omitted for adult patients with osteosarcoma. The cohort included 60 patients aged 16 to 63 years (median age, 27 years). Patients received initial therapy with ifosfamide and cisplatin. Doxorubicin was added after definitive surgery for patients who had less necrosis after initial chemotherapy.[35]
With a median follow-up of 322 months, the 5-year disease-free survival (DFS) rate was 51.8%, and the 5-year OS rate was 64.4%.
At 10 years, the DFS rate was 49.9%, and the OS rate was 64.4%.
At 25 years, the DFS rate was 47.8%, and the OS rate was 55.9%.
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Historically, the extent of tumor necrosis was used in some clinical trials to determine what type of postoperative chemotherapy would be given. In general, if tumor necrosis exceeded 90%, the preoperative chemotherapy regimen was continued. If tumor necrosis was less than 90%, some groups incorporated drugs not previously used in the preoperative therapy.
Patients with less necrosis after initial chemotherapy have an inferior prognosis than patients with more necrosis. The prognosis is still substantially better than the prognosis for patients treated with surgery alone and no adjuvant chemotherapy.
Based on the following evidence, it is inappropriate to conclude that patients with less necrosis have not responded to chemotherapy and that adjuvant chemotherapy should be withheld for these patients. Chemotherapy after definitive surgery should include the agents used in the initial phase of treatment unless there is clear and unequivocal progressive disease during the initial phase of therapy.
Evidence (using the same agents for postoperative chemotherapy):
Early reports from the Memorial Sloan Kettering Cancer Center (MSKCC) suggested that adding cisplatin to postoperative chemotherapy improved the outcome for patients with less than 90% tumor necrosis.[36]
Sources: 36
Early reports from the Memorial Sloan Kettering Cancer Center (MSKCC) suggested that adding cisplatin to postoperative chemotherapy improved the outcome for patients with less than 90% tumor necrosis.[36]
With longer follow-up, the outcome for patients with less than 90% tumor necrosis treated at MSKCC was the same whether they did or did not receive cisplatin in the postoperative phase of treatment.[37]
Sources: 37
In an early experience, the German COSS performed a trial in which the chemotherapy regimen for patients with poor necrosis was changed after initial treatment.[38] The agents used before surgery were discontinued and other agents were substituted.
Sources: 38
In an early experience, the German COSS performed a trial in which the chemotherapy regimen for patients with poor necrosis was changed after initial treatment.[38] The agents used before surgery were discontinued and other agents were substituted.
The results were substantially poorer for these patients than for patients who continued to receive the same agents.
Subsequent trials performed by other groups failed to demonstrate improved EFS when drugs not included in the preoperative regimen (cisplatin) were added to postoperative therapy.[19,39]
A limited-institution pilot trial tested the strategy of discontinuing the agents used in the initial phase of therapy for patients with poorer necrosis. Postoperative therapy consisted of melphalan with autologous stem cell reconstitution.[40]
Sources: 40
A limited-institution pilot trial tested the strategy of discontinuing the agents used in the initial phase of therapy for patients with poorer necrosis. Postoperative therapy consisted of melphalan with autologous stem cell reconstitution.[40]
The 5-year EFS rate for this group was 28%, which was lower than the EFS rates observed in many large series in which agents were continued despite a lesser degree of necrosis.
The international EURAMOS group consortium was formed to conduct a large, prospective, randomized trial to help determine whether modifying the chemotherapy regimen on the basis of the degree of necrosis would improve EFS. All patients received initial therapy with cisplatin, doxorubicin, and high-dose methotrexate (MAP). Patients with more than 90% necrosis were randomly assigned to continue the same chemotherapy after surgery or to receive the same chemotherapy with the addition of interferon alpha-2b.[33][Level of evidence B1] In the same EURAMOS trial, patients with less than 90% necrosis were randomly assigned to continue the same chemotherapy or to receive the same chemotherapy with the addition of high-dose ifosfamide and etoposide (MAPIE).[34][Level of evidence B1]
Sources: 33 · Level of evidence B1 · 34 · Level of evidence B1
The international EURAMOS group consortium was formed to conduct a large, prospective, randomized trial to help determine whether modifying the chemotherapy regimen on the basis of the degree of necrosis would improve EFS. All patients received initial therapy with cisplatin, doxorubicin, and high-dose methotrexate (MAP). Patients with more than 90% necrosis were randomly assigned to continue the same chemotherapy after surgery or to receive the same chemotherapy with the addition of interferon alpha-2b.[33][Level of evidence B1] In the same EURAMOS trial, patients with less than 90% necrosis were randomly assigned to continue the same chemotherapy or to receive the same chemotherapy with the addition of high-dose ifosfamide and etoposide (MAPIE).[34][Level of evidence B1]
The addition of interferon alpha-2b did not improve the probability of EFS.
With a median follow-up of over 61 months, the EFS did not differ between the two groups.
The intensification of treatment in the MAPIE group resulted in greater toxicity than did the treatment in the standard MAP arm.
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
A single-institution retrospective analysis reported on early progression of osteosarcoma before local control.[41] Among 195 patients aged 18 years or younger, 25 (81%) had local-site progression only, and 6 patients had combined local- and metastatic-sites progression. The authors did not prospectively identify patients with clinical features that might suggest telangiectatic osteosarcoma with increased necrosis and hemorrhage, which might be an explanation for apparent progression. For the entire cohort, the 5-year EFS rate was 27.2%, and the OS rate was 31.3%. Patients with good necrosis had better 5-year EFS and OS rates (66.7% and 66.7%, respectively), compared with patients with a poor histological response (21.4% and 25.6%, respectively). However, these results did not reach statistical significance (P = .07 and P = .1).
Sources: 41
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
The Italian Sarcoma Group and the Scandinavian Sarcoma Group performed a clinical trial in patients with osteosarcoma who presented with clinically detectable metastatic disease.[42] Consolidation with high-dose etoposide and carboplatin followed by autologous stem cell reconstitution did not appear to improve outcome and the investigators did not recommend this strategy for the treatment of osteosarcoma.
Sources: 42
Laboratory studies using cell lines and xenografts suggested that bisphosphonates had activity against osteosarcoma.[43] A single-institution clinical trial demonstrated that pamidronate could safely be administered along with multiagent chemotherapy to patients with newly diagnosed osteosarcoma.[43] The French pediatric and adult sarcoma cooperative groups performed a prospective trial for the treatment of osteosarcoma.[44] All patients received multiagent chemotherapy, and patients were randomly assigned to receive or not to receive zoledronate. The addition of zoledronate did not improve EFS.
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
If complete surgical resection is not feasible or if surgical margins are inadequate, radiation therapy may improve the local control rate.[45,46]; [47][Level of evidence C1] Radiation therapy should be considered in patients with osteosarcoma of the head and neck who have positive or uncertain resection margins.[48][Level of evidence C1]
Sources: 45 · 46 · 47 · Level of evidence C1 · 48 · Level of evidence C1
Evidence (radiation therapy for local control):
While it is accepted that the standard approach is primary surgical resection, a retrospective analysis of a small group of highly selective patients reported long-term EFS with external-beam radiation therapy for local control in some patients.[49][Level of evidence C1]
Sources: 49 · Level of evidence C1
Investigators from a single institution reported on 28 children and young adults with osteosarcoma who were treated with radiation therapy for local control. Sixteen patients received radiation therapy during the primary treatment course, and 12 patients received radiation therapy as part of therapy after recurrence.[50]
Sources: 50
Investigators from a single institution reported on 28 children and young adults with osteosarcoma who were treated with radiation therapy for local control. Sixteen patients received radiation therapy during the primary treatment course, and 12 patients received radiation therapy as part of therapy after recurrence.[50]
For patients who received radiation therapy during primary treatment, the cumulative incidence of local failure at 5 years was 25%.
For patients with recurrent disease, the cumulative incidence of local failure at 5 years was 44%.
Local tumor progression was observed in 3 of 13 patients (23%) who were treated with adjuvant radiation therapy after resection, while three of six patients (50%) who received definitive radiation therapy as a sole modality of local control experienced local progression.
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Osteosarcoma of the head and neck occurs in an older population than does osteosarcoma of the extremities.[48,51-54] In the pediatric age group, osteosarcomas of the head and neck are more likely to be low-grade or intermediate-grade tumors than are osteosarcomas of the extremities.[55,56] All reported series emphasize the need for complete surgical resection.[48,51-56][Level of evidence C1] The probability for cure with surgery alone is higher for osteosarcoma of the head and neck than it is for extremity osteosarcoma. When surgical margins are positive, there is a trend for improved survival with adjuvant radiation therapy.[48,53][Level of evidence C1]
Sources: 48 · 51 · 54 · 55 · 56 · 48 · 51 · 56 · Level of evidence C1 · 48 · 53 · Level of evidence C1
There are no randomized trials to assess the efficacy of chemotherapy in patients with osteosarcoma of the head and neck, but several series suggest a benefit.[51,57] Chemotherapy should be considered for younger patients with high-grade osteosarcoma of the head and neck.[55,58]
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Approximately 20% to 25% of patients with osteosarcoma present with clinically detectable metastatic disease. For patients with metastatic disease at initial presentation, roughly 20% will remain continuously free of disease, and roughly 30% will survive 5 years from diagnosis.[1]
Sources: 1
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Treatment options for patients with osteosarcoma or undifferentiated pleomorphic sarcoma (UPS) of bone with metastatic disease at diagnosis include the following:
Chemotherapy.
The chemotherapeutic agents used include high-dose methotrexate, doxorubicin, cisplatin, high-dose ifosfamide, etoposide, and, in some reports, carboplatin or cyclophosphamide.
Evidence (chemotherapy):
In a trial that investigated high-dose ifosfamide (17.5 g per course) in combination with etoposide for patients with newly diagnosed metastatic osteosarcoma, the following was observed:[4] However, similar to localized disease, there is no evidence that the addition of ifosfamide or etoposide contributes to improved event-free survival (EFS) or overall survival (OS) in patients with metastatic disease.
Sources: 4
In a trial that investigated high-dose ifosfamide (17.5 g per course) in combination with etoposide for patients with newly diagnosed metastatic osteosarcoma, the following was observed:[4] However, similar to localized disease, there is no evidence that the addition of ifosfamide or etoposide contributes to improved event-free survival (EFS) or overall survival (OS) in patients with metastatic disease.
The combination produced a complete response in 10% of the patients and a partial response in 49% of the patients.
A study using a factorial design in patients with metastatic osteosarcoma (n = 91) evaluated the addition of either muramyl tripeptide or ifosfamide to a standard chemotherapy regimen that included cisplatin, high-dose methotrexate, and doxorubicin.[5]
Sources: 5
A study using a factorial design in patients with metastatic osteosarcoma (n = 91) evaluated the addition of either muramyl tripeptide or ifosfamide to a standard chemotherapy regimen that included cisplatin, high-dose methotrexate, and doxorubicin.[5]
There was a nominal advantage for the addition of muramyl tripeptide (but not for ifosfamide) in terms of EFS and OS, but criteria for statistical significance were not met.
In the international European and American Osteosarcoma Study (EURAMOS) group consortium, 362 of 2,186 patients (17%) presented with metastasis at diagnosis. Patients were randomly assigned to receive either treatment with cisplatin, doxorubicin, and high-dose methotrexate or cisplatin, doxorubicin, high-dose methotrexate, and ifosfamide.[6][Level of evidence A1]
Sources: 6 · Level of evidence A1
In the international European and American Osteosarcoma Study (EURAMOS) group consortium, 362 of 2,186 patients (17%) presented with metastasis at diagnosis. Patients were randomly assigned to receive either treatment with cisplatin, doxorubicin, and high-dose methotrexate or cisplatin, doxorubicin, high-dose methotrexate, and ifosfamide.[6][Level of evidence A1]
At a median follow-up of 47 months, the 3-year EFS rate was 32% (95% confidence interval [CI], 27%–37%), and the 5-year EFS rate was 28% (95% CI, 23%–33%).
The 3-year OS rate was 56% (95% CI, 50%–61%), and the 5-year OS rate was 45% (95% CI, 39%–50%).
The treatment options for UPS of bone with metastasis at initial presentation are the same as the treatment for osteosarcoma with metastasis. Patients with unresectable or metastatic UPS have a very poor outcome.[7]
Sources: 7
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Treatment options for patients with metastatic lung lesions at diagnosis include the following:
Preoperative chemotherapy followed by surgery to remove the tumor followed by postoperative combination chemotherapy.
Patients with metastatic lung lesions as the sole site of metastatic disease should have the lung lesions resected if possible. Generally, this is performed after the administration of preoperative chemotherapy. After definitive surgical resection of the primary tumor, most clinicians resume systemic chemotherapy before initiating lung surgery to avoid longer delays in the resumption of chemotherapy. In approximately 10% of patients, all lung lesions disappear after preoperative chemotherapy.[3] Complete resection of pulmonary metastatic disease can be achieved in a high percentage of patients with residual lung nodules after preoperative chemotherapy. The long-term survival is poor for patients who do not undergo complete surgical resection of pulmonary metastatic disease.[8,9][Level of evidence B4]
Sources: 3 · 8 · 9 · Level of evidence B4
For patients who present with primary osteosarcoma and metastases limited to the lungs and who achieve complete surgical remission, the 5-year EFS rate is approximately 20% to 25%. Multiple metastatic nodules confer a worse prognosis than do one or two nodules, and bilateral lung involvement is worse than unilateral.[1] Patients with peripheral lung lesions may have a better prognosis than patients with central lesions.[10] Patients with fewer than three nodules confined to one lung may achieve a 5-year EFS rate of approximately 40% to 50%.[1]
A multi-institutional retrospective analysis compared thoracotomy with thoracoscopy for resection of pulmonary metastases in patients with osteosarcoma.[11] The analysis included patients who had pulmonary metastases at diagnosis, patients with pulmonary relapse after initial management of localized disease, and patients with disease progression while on therapy. The authors recognized a significant selection bias for the patients chosen to undergo thoracoscopy. In a Cox regression analysis, controlling for other factors impacting outcome, there was a significantly increased risk of mortality (hazard ratio [HR], 2.11; 95% CI, 1.09–4.09; P = .027) but not pulmonary recurrence (HR, 0.96; 95% CI, 0.52–1.79; P = .90) with a thoracoscopic approach. In a subset analysis limited to patients with oligometastatic disease, thoracoscopy did not increase the risk of mortality (HR, 1.16; 95% CI, 0.64–2.11; P = .62). The ongoing randomized trial (AOST2031 [NCT05235165]) was designed to definitively address this question and the selection bias. This trial will compare the effect of thoracotomy with thoracoscopic surgery.
Sources: 11 · AOST2031 [NCT05235165]
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
The second most common site of metastasis is another bone that is distant from the primary tumor. Patients with metastasis to other bones distant from the primary tumor experience EFS and OS rates of approximately 10%.[1] In a study of patients who presented with primary extremity tumors and synchronous metastasis to other bones, only 3 of 46 patients remained continuously disease-free 5 years later.[12] Patients with transarticular skip lesions have a poor prognosis.[13]
Multifocal osteosarcoma is different from osteosarcoma that presents with a clearly delineated primary lesion and limited bone metastasis. Multifocal osteosarcoma classically presents with symmetrical, metaphyseal lesions, and it may be difficult to determine the primary lesion. Patients with multifocal bone disease at presentation have an extremely poor prognosis, but treatment with systemic chemotherapy and aggressive surgical resection may significantly prolong life.[14,15]
Treatment options for patients with bone metastases with or without lung metastases include the following:
Preoperative chemotherapy followed by surgery to remove the primary tumor. After definitive surgical resection of the primary tumor, most clinicians resume systemic chemotherapy.The timing of surgery to remove metastatic tumors is not well defined. It is usually not attempted at the time of primary surgery because delays of more than 21 days until resumption of chemotherapy can increase the risk of adverse events and death.[16]
Sources: 16
Surgery to remove the primary tumor followed by chemotherapy and then surgical resection of metastatic disease followed by postoperative combination chemotherapy. When the usual treatment course of preoperative chemotherapy followed by surgical ablation of the primary tumor and resection of all overt metastatic disease followed by postoperative combination chemotherapy cannot be used, an alternative treatment approach may be used. This alternative treatment approach begins with surgery for the primary tumor, followed by chemotherapy, and then surgical resection of metastatic disease. This approach may be appropriate in patients with intractable pain, pathological fracture, or uncontrolled infection of the tumor when initiation of chemotherapy could create risk of sepsis.[17]
Sources: 17
Resection of metastatic bone lesions if possible.
Radiation therapy to the extremities. There is evidence that radiation therapy to the extremities may offer some local control.[18]
Sources: 18
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
The following are examples of national and/or institutional clinical trials that are currently being conducted:
AOST2031 (NCT05235165) (Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma): This phase III trial compares the effect of thoracotomy with thoracoscopic surgery (video-assisted thoracoscopic surgery) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). This trial is being done to evaluate the two different surgery methods for these patients and to determine which procedure is better.
Sources: AOST2031 (NCT05235165)
AOST2032 (NCT05691478) (A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma): This trial starts with a feasibility phase for patients with high-risk osteosarcoma who have a resectable primary tumor. The feasibility phase will be followed by a randomized study comparing chemotherapy using methotrexate, doxorubicin, and cisplatin (MAP) with MAP and cabozantinib for patients with newly diagnosed localized and metastatic osteosarcoma.
Sources: AOST2032 (NCT05691478)
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Prognostic factors for recurrent osteosarcoma or undifferentiated pleomorphic sarcoma (UPS) of bone include the following:
Time from diagnosis. In 564 patients who experienced a recurrence, patients whose disease recurred within 2 years of diagnosis had a worse prognosis than patients whose disease recurred after 2 years.[1] In another series of 431 patients, recurrences occurring less than 2 years from diagnosis were also associated with worse outcomes.[5]
Age at initial diagnosis. Older age at initial study enrollment was associated with a worse prognosis after recurrence.[5]
Sources: 5
Presence of metastatic disease at diagnosis. The presence of metastatic disease at initial presentation was associated with a worse prognosis after recurrence.[5]
Sources: 5
Tumor response to preoperative chemotherapy. Patients with a good histological response to initial preoperative chemotherapy had a better overall survival (OS) after recurrence than did patients with a poor initial response.[1]
Sources: 1
Site of metastases. In two large series, the incidence of recurrence by site was as follows: lung only (65%–80%), bone only (8%–10%), local recurrence only (4%–7%), and combined relapse (10%–15%).[4,6] Abdominal metastases are rare but may occur as late as 4 years after diagnosis.[7] The Children's Oncology Group (COG) reported the outcomes of 431 young patients with recurrent osteosarcoma.[5][Level of evidence C3] Patients with recurrences in both lung and bone had worse outcomes than did patients with recurrences in lung only (P = .005).
Sources: 4 · 6 · 7 · 5 · Level of evidence C3
Surgical resectability. Patients with recurrent osteosarcoma should be assessed for surgical resectability because they may sometimes be cured with aggressive surgical resection with or without chemotherapy.[8,6,9-12] Control of osteosarcoma after recurrence depends on complete surgical resection of all sites of clinically detectable metastatic disease. If surgical resection is not attempted or cannot be performed, progression and death are certain. The ability to achieve a complete resection of recurrent disease is the most important prognostic factor at first relapse, with a 5-year survival rate of 20% to 45% after complete resection of metastatic pulmonary tumors and a 20% survival rate after complete resection of metastases at other sites.[4,6,12,13]
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Treatment options for patients with recurrent osteosarcoma or UPS of bone include the following:
Surgery to remove all sites of metastatic disease.
Sources: Surgery
Chemotherapy and targeted therapy.
Sources: Chemotherapy and targeted therapy
Radiopharmaceuticals and radiation therapy.
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Control of osteosarcoma after recurrence depends on complete surgical resection of all sites of clinically detectable metastatic disease.
A multi-institutional retrospective analysis compared thoracotomy with thoracoscopy for resection of pulmonary metastases in patients with osteosarcoma.[14] The analysis included patients who had pulmonary metastases at diagnosis, patients with pulmonary relapse after initial management of localized disease, and patients with disease progression while on therapy. The authors recognized a significant selection bias for the patients chosen to undergo thoracoscopy. In a Cox regression analysis, controlling for other factors impacting outcome, there was a significantly increased risk of mortality (hazard ratio [HR], 2.11; 95% confidence interval [CI], 1.09–4.09; P = .027) but not pulmonary recurrence (HR, 0.96; 95% CI, 0.52–1.79; P = .90) with a thoracoscopic approach. In a subset analysis limited to patients with oligometastatic disease, thoracoscopy did not increase the risk of mortality (HR, 1.16; 95% CI, 0.64–2.11; P = .62). The ongoing randomized trial (AOST2031 [NCT05235165]) was designed to definitively address this question and the selection bias. This trial will compare the effect of thoracotomy with thoracoscopic surgery.
Sources: 14 · AOST2031 [NCT05235165]
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
The role of systemic chemotherapy for the treatment of patients with recurrent osteosarcoma is not well defined. The selection of further systemic treatment depends on many factors, including the site of recurrence, the patient’s previous primary treatment, and individual patient considerations.
Osteosarcoma frequently has a stromal matrix that may further mineralize with tumor necrosis, leaving behind a mass seen on imaging that may or may not have a reduced number of tumor cells within it. Thus, standard Response Evaluation Criteria in Solid Tumors (RECIST) criteria may not be appropriate for evaluation of response to drugs in patients with osteosarcoma. The COG, in an attempt to establish baseline event-free survival (EFS) rates in patients with relapsed osteosarcoma, analyzed the outcomes of these patients from seven single-arm phase II trials. The drugs tested in each trial were determined to be inactive on the basis of radiographic response rates.[15]
Sources: 15
The EFS rate for 96 patients with osteosarcoma and measurable disease was 12% at 4 months (95% CI, 6%–19%).
There was no significant difference in EFS between the trials according to the number of previous treatment regimens or patient age, sex, and ethnicity.
One additional phase II trial with a different study design was reported. In this trial, patients with osteosarcoma and metastases to the lung underwent surgical resection of all lung nodules and then were treated with adjuvant inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF).[15]
Sources: 15
The 12-month EFS rate for the 42 evaluable patients enrolled in this study was 20% (95% CI, 10%–34%).
The following chemotherapy and targeted therapy agents have been studied to treat recurrent osteosarcoma and UPS of bone:
Ifosfamide alone with mesna uroprotection, or in combination with etoposide. Ifosfamide alone with mesna uroprotection, or in combination with etoposide, has been active in as many as one-third of patients with recurrent osteosarcoma who have not previously received this drug.[16-21]
Gemcitabine and docetaxel. A nonrandomized comparison of two doses of gemcitabine, both given with docetaxel, suggested that a higher dose of gemcitabine (900 mg/m2) was associated with a better response rate and longer survival than was a lower dose of gemcitabine (675 mg/m2) for patients with recurrent or refractory osteosarcoma.[22][Level of evidence C1] The combination of gemcitabine (at a dose of 900 mg/m2) and docetaxel has also been reported to have activity in some studies that included patients with unresectable disease.[23-25]; [26][Level of evidence C3]
Sources: 22 · Level of evidence C1 · 23 · 25 · 26 · Level of evidence C3
Cyclophosphamide and etoposide. Cyclophosphamide and etoposide have been shown to have activity in recurrent osteosarcoma.[23]
Sources: 23
Sorafenib. The Italian Sarcoma Group reported rare objective responses and disease stabilization with sorafenib in patients with recurrent osteosarcoma.[27]
Sources: 27
Sorafenib and everolimus. The Italian Sarcoma Group also reported the outcome of patients with metastatic recurrent osteosarcoma treated with the combination of sorafenib and everolimus. They observed two partial responses and two minor responses in 38 patients; 17 of 38 patients were progression free at 6 months from study entry but toxicity was greater than with sorafenib monotherapy.[28][Level of evidence B4]
Sources: 28 · Level of evidence B4
Regorafenib. Two prospective, randomized, double-blind trials have evaluated the role of regorafenib in the treatment of metastatic recurrent osteosarcoma. Both studies used the approved treatment regimen of 160 mg by mouth daily for 21 days followed by 7 days without treatment. The trial conducted in France included patients who were randomly assigned 2:1 between regorafenib and placebo and allowed crossover for patients assigned to placebo.[29] Seventeen of 26 patients (65%; one-sided 95% CI, 47%) in the regorafenib group did not have disease progression at 8 weeks, compared with 0 of 12 patients in the placebo group. The Sarcoma Alliance for Research Collaboration (SARC) group randomly assigned adult patients 1:1 between regorafenib and placebo.[30] Median progression-free survival (PFS) was significantly improved with regorafenib versus placebo: 3.6 months (95% CI, 2.0–7.6 months) versus 1.7 months (95% CI, 1.2–1.8 months), respectively (HR, 0.42; 95% CI, 0.21–0.85; P = .017).
Dinutuximab in combination with GM-CSF. The COG performed a phase II study of dinutuximab, an antidisialoganglioside antibody, in combination with GM-CSF for patients with recurrent osteosarcoma. Of 39 patients, 28 experienced an event, and only 28.2% (95% CI, 15%–44.9%) of patients were event-free at the 12-month benchmark. Dinutuximab did not demonstrate sufficient evidence of efficacy.[31]
Sources: 31
Denosumab. The COG performed a phase II study of denosumab, a fully human monoclonal antibody to the receptor activator of nuclear factor-kappa beta ligand (RANKL). Patients aged 11 to 49 years with recurrent osteosarcoma were eligible for the study. Patients with measurable disease were eligible for cohort 1, and patients who underwent complete surgical resection of all sites of recurrent disease were eligible for cohort 2. The event-free rate did not exceed the historical rate experienced in previous COG trials to meet the study defined efficacy criteria in either cohort.[32]
Sources: 32
Lenvatinib with ifosfamide and etoposide. A multi-institutional group performed a phase I/II study using a combination of lenvatinib, ifosfamide, and etoposide to treat patients with relapsed or refractory osteosarcoma.[33][Level of evidence B4] The study suggested phase II doses for each drug: 1) 14 mg/m2 per day of lenvatinib (with a daily dose cap of 24 mg), 2) 100 mg/m2 per day of etoposide, and 3) 3,000 mg/m2 per day of ifosfamide. These drugs were given to patients intravenously on days 1 to 3 of each 3-week cycle for five cycles at most. Thirty-five patients from the phase I (cohort 3A; n = 15) and phase II (cohort 3B; n = 20) trials were treated at the recommended phase II doses, and their results were pooled. Eighteen of 35 patients had PFS rates of 51% (95% CI, 34%–69%) after 4 months, per the binomial estimate.
Sources: 33 · Level of evidence B4
Cabozantinib. A phase II clinical trial of this VEGFR2 and MET inhibitor evaluated 43 patients aged 12 years and older with relapsed osteosarcoma, 39 of whom had pulmonary metastases. The 6-month PFS rate was 33%, and five patients (12%) had a partial response.[34]
Sources: 34
Apatinib. A phase II clinical trial of this VEGFR2 inhibitor enrolled 37 patients aged 16 years and older. Sixteen patients (43%) had a partial response, and the 4-month PFS rate was 57%.[35] In a retrospective review of 19 patients with osteosarcoma who were treated with apatinib, 3 patients had a partial response (16%).[36]
Anlotinib. A retrospective analysis reported the efficacy of the multitargeted tyrosine kinase inhibitor anlotinib in patients with recurrent metastatic osteosarcoma.[37] The study included 15 patients who were treated in China between June 2018 and April 2020. The median PFS was 9.8 months (± 0.9 months). The 6-month PFS rate was 73%, and the 10-month PFS rate was 33%. The median OS was 11.4 months (± 0.6 months). No patients achieved complete responses.
Sources: 37
Immunotherapy. Osteosarcoma frequently expresses PD-1, but trials of PD-1 inhibitors have been disappointing.[38-40] In these three studies, objective responses were observed in 1 of 14, 0 of 10, and 1 of 19 patients. HER2-expressing chimeric antigen receptor (CAR) T-cell therapy is also being studied.[41]
High-dose chemotherapy with autologous hematopoietic stem cell transplant (HSCT). A study analyzed the addition of high-dose chemotherapy with autologous HSCT to treat Korean patients with relapsed osteosarcoma who achieved a complete response to salvage therapy.[42] Among 25 patients who achieved a complete response with salvage therapy, 15 were assigned to receive high-dose chemotherapy with autologous HSCT by investigator choice. In a subgroup analysis of outcomes in patients who achieved a complete response, there were no significant differences in the 5-year OS rates between patients who did and did not receive high-dose chemotherapy with autologous HSCT (83.9% ± 0.1% for 13 of 15 patients vs. 80.0% ± 0.1% for 8 of 10 patients, respectively; P = .923).
Sources: 42
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
High-dose samarium Sm 153-ethylenediamine tetramethylene phosphonic acid (153Sm-EDTMP) coupled with peripheral blood stem cell support may provide significant pain palliation in patients with bone metastases.[43-46] Toxicity of 153Sm-EDTMP is primarily hematologic.[47][Level of evidence C2]
Sources: 43 · 46 · 47 · Level of evidence C2
A single-institution retrospective review reported that high-dose fraction radiation therapy (2 Gy/fraction) was a useful form of palliation for patients with recurrent osteosarcoma.[48][Level of evidence C3] Thirty-two courses of palliative radiation therapy were given to 20 patients with symptomatic metastatic and/or locally recurrent primary disease. Twenty-four of the 32 courses (75%) were associated with symptom improvement. Higher doses of radiation therapy correlated with longer durations of symptom response.
Sources: 48 · Level of evidence C3
Palliation of painful lesions in children with recurrent or progressive disease can be achieved using a short course (10 or fewer fractions) of radiation therapy. In a retrospective study of 213 children with various malignancies, who were treated with short-course radiation therapy, 85% of patients had complete or partial pain relief, with low levels of toxicity.[49]
Sources: 49
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Treatment options for patients with osteosarcoma or UPS of bone that has recurred locally include the following:
Surgery to remove the tumor.
The postrelapse outcome of patients who have a local recurrence is quite poor.[50-52] Survival of patients with local recurrences and either previous or concurrent systemic metastases is poor.[53]
Two retrospective, single-institution series reported a survival rate of 10% to 40% after local recurrence without associated systemic metastasis.[53-56]
A retrospective review from the Italian Sarcoma Group identified 62 patients (median age, 21 years) with local recurrences.[57] With a median follow-up of 43 months (range, 5–235 months), the 5-year post–local relapse survival rate was 37%, significantly better for patients with a longer local recurrence–free interval (≤24 months, 31% vs. >24 months, 61.5%; P = .03), absence of distant metastases (no distant metastases, 56% vs. distant metastases, 11.5%; P = .0001), and achievement of second complete remission (CR) by surgical resection (no second CR, 0% vs. second CR, 58.5%; P = .0001). No difference in post–local relapse survival was found according to age, and there was no benefit from chemotherapy administration.
Sources: 57
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Treatment options for patients with osteosarcoma and UPS of bone that has recurred in the lung only include the following:
Surgery to remove the tumor.
Chemotherapy or targeted therapy. For more information, see the Chemotherapy and targeted therapy section.
Sources: Chemotherapy and targeted therapy
Radiation therapy.
Repeated resections of pulmonary recurrences can lead to extended disease control and, possibly, cure for some patients.[13,58] The survival rate is less than 5% for patients with unresectable metastatic disease.[6,59] The 5-year EFS rate ranges from 20% to 45% for patients who have complete surgical resection of all pulmonary metastases.[4,12,13]; [60][Level of evidence C1]
Sources: 13 · 58 · 6 · 59 · 4 · 12 · 13 · 60 · Level of evidence C1
Fewer pulmonary nodules.
Unilateral pulmonary metastases.
Longer intervals between primary tumor resection and metastases.
Tumor location in the periphery of the lung.
Approximately 50% of patients with one isolated pulmonary lesion more than 1 year after diagnosis were long-term survivors after metastasectomy. Chemotherapy did not appear to offer an advantage.[64][Level of evidence C1]
Sources: 64 · Level of evidence C1
Control of osteosarcoma requires surgical resection of all macroscopic tumors. However, recommendations are conflicting regarding the surgical approach to the treatment of pulmonary metastases in osteosarcoma. Several options are available to resect pulmonary nodules in a patient with osteosarcoma, including thoracoscopy and thoracotomy with palpation of the collapsed lung. When patients have nodules identified only in one lung, some surgeons advocate thoracoscopy, some advocate unilateral thoracotomy, and some advocate bilateral thoracotomy. Bilateral thoracotomy can be performed as a single surgical procedure with a median sternotomy or a clamshell approach, or by staged bilateral thoracotomies.
Evidence (surgical approach for lung-only recurrence of osteosarcoma and UPS of bone):
The St. Jude Children’s Research Hospital reported on 81 patients who had pulmonary nodules identified at initial presentation in only one lung by computed tomography (CT) scan.[65] They performed unilateral thoracotomy and did not explore the contralateral hemithorax. At the time of thoracotomy, 44 of 81 patients had a solitary nodule identified; 15 of 81 patients had two nodules identified; 16 of 81 patients had three to five nodules identified; and 6 of 81 patients had more than five nodules identified. Additional patients who were considered unresectable were not included in the analysis.
Sources: 65
The St. Jude Children’s Research Hospital reported on 81 patients who had pulmonary nodules identified at initial presentation in only one lung by computed tomography (CT) scan.[65] They performed unilateral thoracotomy and did not explore the contralateral hemithorax. At the time of thoracotomy, 44 of 81 patients had a solitary nodule identified; 15 of 81 patients had two nodules identified; 16 of 81 patients had three to five nodules identified; and 6 of 81 patients had more than five nodules identified. Additional patients who were considered unresectable were not included in the analysis.
Thirty-nine of 81 patients had subsequent pulmonary recurrence; for most patients, recurrence occurred within 6 months.
Within the first 6 months, 9 of 81 patients had ipsilateral recurrence, and 10 of 81 patients had a contralateral recurrence. By 2 years after initial thoracotomy, 13 of 81 patients had ipsilateral recurrence; 19 of 81 patients had contralateral recurrence; and 2 of 81 patients had bilateral recurrence.
OS was similar for patients with ipsilateral and bilateral recurrence.
The Memorial Sloan Kettering Cancer Center reported on pulmonary metastatic disease recurrence after initial therapy for osteosarcoma. Fourteen patients had pulmonary nodules identified in only one lung by CT scan. Nine patients were identified less than 2 years from initial diagnosis (early metastases), and five patients were identified more than 2 years from initial diagnosis (late metastases).[62] Seven of nine patients with early metastases had staged contralateral thoracotomies, and six of seven had nodules removed from the contralateral lung, despite negative CT scan findings.
Sources: 62
The Memorial Sloan Kettering Cancer Center reported on pulmonary metastatic disease recurrence after initial therapy for osteosarcoma. Fourteen patients had pulmonary nodules identified in only one lung by CT scan. Nine patients were identified less than 2 years from initial diagnosis (early metastases), and five patients were identified more than 2 years from initial diagnosis (late metastases).[62] Seven of nine patients with early metastases had staged contralateral thoracotomies, and six of seven had nodules removed from the contralateral lung, despite negative CT scan findings.
The lack of a comparison group precludes evaluation of the impact of the contralateral thoracotomy on subsequent EFS or OS.
The same group expanded their analysis to include a retrospective review of 161 thoracotomies performed in 88 patients with osteosarcoma metastatic to the lung.[66] In this expanded series, CT failed to identify one-third of pulmonary metastases confirmed by pathological examination.
Sources: 66
The COG is conducting a randomized trial (AOST2031 [NCT05235165]) to compare the effect of thoracotomy with thoracoscopic surgery to remove lung metastases. For more information, see the Treatment Options Under Clinical Evaluation section.
Sources: AOST2031 [NCT05235165] · Treatment Options Under Clinical Evaluation
External-beam radiation therapy can provide local control of recurrent unresectable disease, symptomatic, and/or metastatic disease. Radiation therapy techniques allow for the delivery of very conformal high doses, known as stereotactic ablative radiation therapy (SABR) or stereotactic body radiation therapy (SBRT). SBRT and SABR administer treatment with high conformality and precision over a short period of time, providing good palliation and local control.[67]
Sources: 67
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Treatment options for patients with osteosarcoma or UPS of bone that has recurred in the bone only include the following:
Surgery to remove the tumor.
153Sm-EDTMP with or without stem cell support.
Chemotherapy or targeted therapy. For more information, see the Chemotherapy and targeted therapy section.
Sources: Chemotherapy and targeted therapy
Radiation therapy.
Patients with osteosarcoma who develop bone metastases have a poor prognosis. In one large series, the 5-year EFS rate was 11%.[68] Patients with late solitary bone relapse have a 5-year EFS rate of approximately 30%.[68-71]
For patients with multiple unresectable bone lesions, 153Sm-EDTMP with or without stem cell support may produce stable disease and/or provide pain relief.[47]
Sources: 47
External-beam radiation therapy can provide local control of recurrent unresectable disease, symptomatic, and/or metastatic disease. Radiation therapy techniques allow for the delivery of very conformal high doses, known as SABR or SBRT. SBRT and SABR administer treatment with high conformality and precision over a short period of time, providing good palliation and local control.[67]
Sources: 67
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Treatment options for patients with osteosarcoma or UPS of bone that has recurred twice include the following:
Surgery to remove the tumor and/or chemotherapy.
Chemotherapy or targeted therapy. For more information, see the Chemotherapy and targeted therapy section.
Sources: Chemotherapy and targeted therapy
Evidence (surgery and/or chemotherapy):
The cooperative German-Austrian-Swiss osteosarcoma study group reported on 249 patients who had a second recurrence of osteosarcoma. The main therapy was repeated surgical resection of recurrent disease.[72]
Sources: 72
The cooperative German-Austrian-Swiss osteosarcoma study group reported on 249 patients who had a second recurrence of osteosarcoma. The main therapy was repeated surgical resection of recurrent disease.[72]
Of these patients, 197 died and 37 were alive in CR (24 patients after a third complete response and 13 patients after a fourth or subsequent complete response).
Fifteen patients who did not achieve surgical remission remained alive, but follow-up for these patients was extremely short.
The Spanish Group for Research on Sarcoma reported the results of a phase II trial of patients with relapsed or refractory osteosarcoma who were treated with gemcitabine and sirolimus.[73][Level of evidence C3]
Sources: 73 · Level of evidence C3
The Spanish Group for Research on Sarcoma reported the results of a phase II trial of patients with relapsed or refractory osteosarcoma who were treated with gemcitabine and sirolimus.[73][Level of evidence C3]
The PFS rate at 4 months was 44%.
After central radiological review of 33 assessable patients, 2 partial responses and 14 disease stabilizations (48.5%) were reported.
The COG reported the outcomes of patients with recurrent osteosarcoma from seven phase II trials, all of which were assessed to have shown no treatment benefit.[15]
Sources: 15
The COG reported the outcomes of patients with recurrent osteosarcoma from seven phase II trials, all of which were assessed to have shown no treatment benefit.[15]
The EFS rate for 96 patients with osteosarcoma and measurable disease was 12% at 4 months (95% CI, 6%–19%).
There was no significant difference in EFS between the trials according to the number of previous treatment regimens or patient age, sex, and ethnicity.
One additional phase II trial with a different study design was reported. In this trial, patients with osteosarcoma and metastases to the lung underwent surgical resection of all lung nodules and then were treated with adjuvant inhaled GM-CSF.[15]
Sources: 15
One additional phase II trial with a different study design was reported. In this trial, patients with osteosarcoma and metastases to the lung underwent surgical resection of all lung nodules and then were treated with adjuvant inhaled GM-CSF.[15]
The 12-month EFS rate for the 42 evaluable patients enrolled in this study was 20% (95% CI, 10%–34%).
Source: Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 2, 2024. Captured 2026-09-09.
Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Sources: NCI website · ClinicalTrials.gov website
The following are examples of national and/or institutional clinical trials that are currently being conducted:
GD2-CAR PERSIST (NCT04539366) (Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults with Relapsed/Refractory Osteosarcoma and Neuroblastoma): This is a phase I trial to determine the side effects and best dose of GD2CART to be effective against GD2-positive tumor cells.
Sources: GD2-CAR PERSIST (NCT04539366)
AOST2031 (NCT05235165) (Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma): This phase III trial compares the effect of thoracotomy with thoracoscopic surgery (video-assisted thoracoscopic surgery) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). This trial is being done to evaluate the two different surgery methods for these patients and to determine which procedure is better.
Sources: AOST2031 (NCT05235165)
NCT03811886 (Natalizumab for the Treatment of Recurrent, Refractory, or Progressive Pulmonary Metastatic Osteosarcoma): This is a phase I/II trial evaluating the safety of and response to natalizumab for patients with lung metastases that have progressed, relapsed, or become refractory to systemic therapy.
Sources: NCT03811886
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
A risk factor is anything that increases the chance of getting a disease. Not every child with one or more of these risk factors will develop osteosarcoma. And it will develop in some children who don't have a known risk factor. Risk factors for osteosarcoma include:
past treatment with chemotherapy or radiation therapy
Sources: chemotherapy · radiation therapy
having a certain change in the RB1 gene
Sources: gene
having certain conditions, such as:
Sources: conditions
Diamond-Blackfan anemia
Sources: Diamond-Blackfan anemia
Li-Fraumeni syndrome
Sources: Li-Fraumeni syndrome
Paget disease
Sources: Paget disease
hereditary retinoblastoma
Sources: hereditary · retinoblastoma
Rothmund-Thomson syndrome
Sources: Rothmund-Thomson syndrome
Werner syndrome
Sources: Werner syndrome
Talk with your child's doctor if you think your child may be at risk.
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
If your child has been diagnosed with osteosarcoma or UPS, you likely have questions about how serious the cancer is and your child's chances of survival. The likely outcome or course of a disease is called prognosis.
Many factors affect prognosis and treatment options.
Factors that may affect your child's prognosis before treatment include:
where the tumor is in the body and whether tumors formed in more than one bone
whether multiple tumors have formed in the same bone
the size of the tumor
whether the cancer has spread to other parts of the body and, if so, where it has spread
the type of tumor (based on how the cancer cells look under a microscope)
your child's sex, age, and weight at the time of diagnosis
whether your child has been treated for a different cancer in the past
whether your child has certain genetic conditions
Sources: genetic
Factors that may affect your child's prognosis after treatment include:
how well the chemotherapy worked
Sources: chemotherapy
whether the tumor was completely removed by surgery
whether the cancer has recurred (come back) within 5 years of diagnosis
Sources: recurred
No two people are alike, and response to treatment can vary greatly. Your child's cancer care team is in the best position to talk with you about your child's prognosis.
Treatment options for osteosarcoma and UPS depend on:
where the tumor is in the body and if it has spread
the size of the tumor
the grade of the cancer
Sources: grade
whether the bones are still growing
your child's age and overall health
your child's and family's goals, such as being able to participate in sports, or concerns about physical appearance
whether the cancer is newly diagnosed or has recurred after treatment
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
The cancer may come back in the bone or in other parts of the body. Osteosarcoma and UPS most often recur in the lung, bone, or both. When osteosarcoma recurs, it is usually within 18 months after treatment is completed.
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
There are different types of treatment for children with osteosarcoma or undifferentiated pleomorphic sarcoma (UPS).
Children with osteosarcoma or UPS should have their treatment planned by a team of health care providers who are experts in treating cancer in children.
The following types of treatment are used:
The following types of treatment are used:
Surgery
Chemotherapy
Radiation therapy
Samarium
You may want to think about your child taking part in a clinical trial.
Treatment for osteosarcoma or UPS may cause side effects.
Follow-up care may be needed.
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
You and your child's care team will work together to decide treatment. Many factors will be considered, such as where the cancer is located and your child's age and overall health.
Your child's treatment plan will include information about the tumor, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child's care team before treatment begins about what to expect. For help every step of the way, visit our booklet, Children with Cancer: A Guide for Parents.
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of osteosarcoma. The pediatric oncologist works with other health care providers who are experts in treating osteosarcoma and UPS and who specialize in certain areas of medicine. Other specialists may include:
pediatrician
Sources: pediatrician
orthopedic surgeon who has experience treating bone tumors
Sources: surgeon
radiation oncologist
Sources: radiation oncologist
rehabilitation specialist
Sources: rehabilitation specialist
pediatric nurse specialist
Sources: pediatric nurse specialist
social worker
Sources: social worker
child-life specialist
Sources: child-life specialist
psychologist
Sources: psychologist
fertility specialist
Sources: fertility specialist
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
Surgery to remove the entire tumor will be done when possible. Chemotherapy may be given before surgery to make the tumor smaller. This is called neoadjuvant chemotherapy. Chemotherapy is given so less bone tissue needs to be removed and there are fewer problems after surgery.
Sources: Chemotherapy · neoadjuvant
The following types of surgery may be done:
Wide local excision removes the cancer and some healthy tissue around it.
Sources: Wide local excision
Limb-sparing surgery removes a tumor in an arm or leg without amputation. Limb-sparing surgery is often an option for children with osteosarcoma in an arm or leg. The tumor is removed by wide local excision. The removed tissue and bone may be replaced with a graft using tissue and bone taken from another part of the body, or with an implant such as artificial bone. If a fracture is found at the time of diagnosis or during chemotherapy before surgery, limb-sparing surgery may still be possible in some cases. If the surgeon is not able to remove all of the tumor and enough healthy tissue around it, an amputation may be done.
Sources: Limb-sparing surgery · amputation · excision · graft · implant
Amputation removes part or all of an arm or leg. This may be done when it is not possible to remove all of the tumor in limb-sparing surgery. If prosthesis is part of the plan, fitting and training will take place with a prosthetist (a specialist in artificial limbs) over several weeks to months.
Sources: prosthesis
Rotationplasty removes the tumor and the knee joint. The part of the leg that remains below the knee is then attached to the part of the leg that remains above the knee, with the foot facing backward and the ankle acting as a knee. A prosthesis may then be attached to the foot.
Sources: Rotationplasty
Studies have shown that survival is the same whether the first surgery done is a limb-sparing surgery or an amputation.
Sources: survival
After the doctor removes all the cancer that can be seen at the time of the surgery, chemotherapy is given to kill any cancer cells that are left. Treatment given after the surgery to lower the risk that the cancer will come back is called adjuvant therapy.
Sources: adjuvant therapy
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells. Chemotherapy either kills the cancer cells or stops them from dividing. Chemotherapy may be given alone or with other types of treatment.
Chemotherapy for osteosarcoma and UPS is injected into a vein. When given this way, the drugs enter the bloodstream and can reach cancer cells throughout the body. Chemotherapy is usually given before and after surgery to remove the tumor.
Sources: injected
Chemotherapy drugs used alone or in combination to treat osteosarcoma include:
carboplatin
Sources: carboplatin
cisplatin
Sources: cisplatin
cyclophosphamide
Sources: cyclophosphamide
docetaxel
Sources: docetaxel
doxorubicin
Sources: doxorubicin
etoposide
Sources: etoposide
gemcitabine
Sources: gemcitabine
ifosfamide
Sources: ifosfamide
methotrexate
Sources: methotrexate
Other chemotherapy drugs not listed here may also be used.
Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer.
Sources: Chemotherapy to Treat Cancer
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Osteosarcoma is treated with external beam radiation therapy. This type of therapy uses a machine outside the body to send radiation toward the area of the body with cancer.
Osteosarcoma and UPS cells are not killed easily by external radiation therapy. It may be used when a small amount of cancer is left after surgery, used together with other treatments, or used as palliative therapy to relieve symptoms caused by the tumor in the bone.
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
Samarium is a radioactive drug that targets tumor cells in a bone. It helps relieve pain caused by cancer in the bone and it also kills blood cells in the bone marrow. It is used to treat osteosarcoma that has come back in a different bone after treatment.
Sources: Samarium · radioactive drug · bone marrow
Treatment with samarium may be followed by stem cell transplant. Before treatment with samarium, stem cells (immature blood cells) are removed from the child's blood or bone marrow and are frozen and stored. After treatment with samarium is complete, the stored stem cells are thawed and given back to the child through an infusion. These reinfused stem cells grow into (and restore) the body's blood cells.
Sources: stem cell transplant · infusion
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
For some children, joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.
You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.
Sources: clinical trial search · ClinicalTrials.gov
Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.
Sources: Clinical Trials Information for Patients and Caregivers
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
Cancer treatments can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.
To learn more about side effects that begin during treatment for cancer, visit Side Effects.
Sources: side effects · Side Effects
Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:
physical problems, such as infertility
changes in mood, feelings, thinking, learning, or memory
second cancers (new types of cancer), such as breast cancer or acute myeloid leukemia
Sources: breast cancer · acute myeloid leukemia
Some late effects may be treated or controlled. It is important to talk with your child's doctors about the effects cancer treatment can have on your child. Learn more about Late Effects of Treatment for Childhood Cancer.
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
As your child goes through treatment, they will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.
Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your child's condition has changed or if the cancer has recurred (come back).
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
Treatment of newly diagnosed localized osteosarcoma and UPS of bone may include:
Sources: localized
surgery to remove the tumor
chemotherapy before or after surgery to remove the tumor
radiation therapy if surgery cannot be done or if the tumor was not completely removed by surgery
Learn about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
Lung Metastasis
When osteosarcoma or UPS spreads, it usually spreads to the lung. Treatment of newly diagnosed osteosarcoma and UPS that has spread to the lung may include chemotherapy followed by surgery to remove the primary cancer and more chemotherapy. Then, the doctor will remove the cancer in the lung and give additional chemotherapy.
Sources: primary cancer
Bone Metastasis or Bone with Lung Metastasis
Osteosarcoma and UPS may spread to a distant bone or to both the lung and a distant bone. Treatment of newly diagnosed osteosarcoma and UPS that has spread to a distant bone or to both the lung and a distant bone may include:
Chemotherapy followed by surgery to remove the primary cancer. More chemotherapy is given after surgery. This may be followed by surgery to remove cancer that has spread to other areas of the body.
Surgery to remove the primary cancer, followed by chemotherapy. Then the doctor will remove the cancer that has spread to other parts of the body and give combination chemotherapy.
Surgery alone to remove cancer that has spread to a distant bone.
Radiation therapy.
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
Source: Osteosarcoma Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: February 25, 2025. Captured 2026-09-09.
Treatment depends on where the cancer recurred and whether it has recurred more than once.
Sources: recurred
For tumors that have recurred in the same bone where the cancer started, treatment is surgery.
For tumors that have recurred in the lung only, treatment may include:
For tumors that have recurred in the lung only, treatment may include:
surgery to remove the tumor
chemotherapy
radiation therapy
For tumors that have recurred in bones other than where the cancer started, treatment may include:
For tumors that have recurred in bones other than where the cancer started, treatment may include:
surgery to remove the tumor
chemotherapy
radiation therapy
samarium with or without stem cells, as palliative treatment to relieve pain and improve quality of life
Sources: stem cells · palliative treatment · quality of life
For tumors that have recurred twice, treatment may include:
For tumors that have recurred twice, treatment may include:
surgery to remove the cancer and chemotherapy
chemotherapy alone
Learn more about these treatments in the Treatment Option Overview.
Sources: Treatment Option Overview
Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.
Sources: clinical trial search · General information
GCT, Giant Cell Tumor of Bone
ClinicalTrials.gov recordCancer, Giant Cell Tumors, Giant Cell Tumor of Bone, Benign Giant Cell Tumors
ClinicalTrials.gov recordPigmented Villonodular Synovitis, Giant Cell Tumors of the Tendon Sheath, Tenosynovial Giant Cell Tumor
ClinicalTrials.gov recordGiant Cell Tumor of Bone
ClinicalTrials.gov recordPulmonary Metastatic Osteosarcoma (pOS)
ClinicalTrials.gov recordOsteosarcoma
ClinicalTrials.gov recordRecurrent Childhood Neuroblastoma, Recurrent Childhood Osteosarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Childhood Neuroblastoma, Refractory Childhood...
ClinicalTrials.gov recordTenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
ClinicalTrials.gov recordMetastatic Malignant Neoplasm in the Lung, Metastatic Osteosarcoma, Osteosarcoma
ClinicalTrials.gov recordHigh Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Secondary Osteosarcoma
ClinicalTrials.gov recordOsteosarcoma, Malignant Fibrous Histiocytoma (MFH) of Bone
ClinicalTrials.gov record( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
1.2 Giant Cell Tumor of Bone Bilprevda is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity...
( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
1.2 Giant Cell Tumor of Bone Denosumab-bmwo is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe...
Giant Cell Tumor
Giant Cell Tumor of Bone
( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Treatment of Localized Osteosarcoma and UPS of Bone
Treatment of Localized Osteosarcoma and UPS of Bone
Treatment of Osteosarcoma and UPS of Bone With Metastatic Disease at Diagnosis
Treatment of Osteosarcoma and UPS of Bone With Metastatic Disease at Diagnosis
1.2 Giant Cell Tumor of Bone Osenvelt is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see...
Osteosarcoma
( 1.1 ) Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
Treatment of Recurrent Osteosarcoma and UPS of Bone
Treatment of Recurrent Osteosarcoma and UPS of Bone
Tenosynovial Giant Cell Tumor
Tenosynovial Giant Cell Tumor, Diffuse Type
Undifferentiated Pleomorphic Sarcoma of Bone
• Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.
1.2 Giant Cell Tumor of Bone Xgeva is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see...
1.2 Giant Cell Tumor of Bone Xtrenbo is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity [see...
Aukelso is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature...
DailyMed labelBilprevda is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally...
DailyMed labelBomyntra is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature...
DailyMed labelDenosumab-bmwo is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally...
DailyMed labelJubereq is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature...
DailyMed labelOsenvelt is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature...
DailyMed labelOziltus is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature...
DailyMed labelROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. ROMVIMZA is a kinase...
DailyMed labelTURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TURALIO is a kinase...
DailyMed labelWyost is a RANK ligand (RANKL) inhibitor indicated for: • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) • Treatment of adults and skeletally...
DailyMed labelXgeva is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature...
DailyMed labelXtrenbo is a RANK ligand (RANKL) inhibitor indicated for: Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) Treatment of adults and skeletally mature...
DailyMed label